Most cited papers from Romark (United States)

Romark (United States)

What are the most cited papers from Romark (United States)?

The most cited paper from Romark (United States) is "Nitazoxanide: A first-in-class broad-spectrum antiviral agent" (Jean‐François Rossignol, 2014), with 578 citations. Next come "Treatment of Diarrhea Caused by Cryptosporidium parvum: A Prospective Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide" (359) and "Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus" (301).

Published TypeFieldAccessCitations

Showing 50 of 91 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Nitazoxanide: A first-in-class broad-spectrum antiviral agent Jean‐François Rossignol · Antiviral Research Open access	6 Aug 2014	578
2	Treatment of Diarrhea Caused by Cryptosporidium parvum: A Prospective Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide Jean-François Rossignol, Ayman Ayoub, Marc S. Ayers · The Journal of Infectious Diseases	Jul 2001	359
3	Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus Jean‐François Rossignol · Journal of Infection and Public Health Open access	18 Apr 2016	301
4	Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial Jason Haffizulla, Aaron L. Hartman, Melanie Hoppers et al. · The Lancet Infectious Diseases Open access	19 May 2014	264
5	Nitazoxanide for the Treatment of Clostridium difficile Colitis Daniel M. Musher, Nancy D. Logan, Richard J. Hamill et al. · Clinical Infectious Diseases	13 Jul 2006	250
6	Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication Brent E. Korba, Abigail Montero, Kristine Farrar et al. · Antiviral Research	5 Sep 2007	218
7	Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial Jean‐François Rossignol, Mona Abu‐Zekry, Abeer Khalaf Hussein et al. · The Lancet	14 Jun 2006	202
8	Nitazoxanide in the treatment of viral gastroenteritis: a randomized double‐blind placebo‐controlled clinical trial Jean François Rossignol, Y. El-Gohary · Alimentary Pharmacology & Therapeutics	27 Oct 2006	186
9	Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study Daniel M. Musher, Nancy D. Logan, Adam M. Bressler et al. · Clinical Infectious Diseases	9 Jan 2009	186
10	Cryptosporidium and Giardia: Treatment options and prospects for new drugs Jean‐François Rossignol · Experimental Parasitology	25 Jul 2009	185
11	A double-‘blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in aids patients in Mexico Jean‐François Rossignol, Hilda Hidalgo, M. Feregrino et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene	Nov 1998	175
12	Treatment of Diarrhea Caused byGiardia intestinalisandEntamoeba histolyticaorE. dispar:A Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide Jean‐François Rossignol, Ayman Ayoub, Marc S. Ayers · The Journal of Infectious Diseases Open access	Aug 2001	158
13	Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean‐François Rossignol, Asem Ahmed Elfert, Yehia El–Gohary et al. · Gastroenterology Open access	20 Nov 2008	147
14	Effect of Nitazoxanide in Diarrhea and Enteritis Caused by Cryptosporidium Species Jean‐François Rossignol, Samir M. Kabil, Yehia El–Gohary et al. · Clinical Gastroenterology and Hepatology Open access	Mar 2006	142
15	In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes Mirjam Walker, Jean François Rossignol, Paul Robert Torgerson et al. · Journal of Antimicrobial Chemotherapy Open access	29 Jul 2004	118
16	Identification of Isoflavone Derivatives as Effective Anticryptosporidial Agents in Vitro and in Vivo Andrew V. Stachulski, Neil G. Berry, Audrey Low et al. · Journal of Medicinal Chemistry	25 Jan 2006	114
17	In Vitro Parasiticidal Effect of Nitazoxanide against Echinococcus multilocularis Metacestodes Marianne Stettler, Renate Fink, Mirjam Walker et al. · Antimicrobial Agents and Chemotherapy Open access	23 Jan 2003	109
18	Effect of Nitazoxanide in Persistent Diarrhea and Enteritis Associated With Blastocystis hominis Jean‐François Rossignol, S KABIL, Mohamed Said et al. · Clinical Gastroenterology and Hepatology Open access	Oct 2005	108
19	Nitazoxanide in the treatment of amoebiasis Jean‐François Rossignol, Samir M. Kabil, Yehia El–Gohary et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene	21 Jul 2007	104
20	The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2α Via Protein Kinase Activated by Double-Stranded RNA Activation Menashe Elazar, Michael Liu, Sean A. McKenna et al. · Gastroenterology	5 Aug 2009	100
21	Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity Marianne Stettler, Jean François Rossignol, Renate Fink et al. · International Journal for Parasitology	27 Feb 2004	99
22	Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro Giuseppe Belardo, Orlando Cenciarelli, Simone La Frazia et al. · Antimicrobial Agents and Chemotherapy Open access	2 Dec 2014	93
23	Nitazoxanide, a Potential Drug for Eradication of Helicobacter pylori with No Cross-Resistance to Metronidazole Françis Mégraud, Alessandra Occhialini, Jean François Rossignol · Antimicrobial Agents and Chemotherapy Open access	Nov 1998	92
24	Thiazolides, a New Class of Antiviral Agents Effective against Rotavirus Infection, Target Viral Morphogenesis, Inhibiting Viroplasm Formation Simone La Frazia, Alessandra Ciucci, Francesca Arnoldi et al. · Journal of Virology Open access	8 Aug 2013	83
25	Thiazolides as Novel Antiviral Agents. 1. Inhibition of Hepatitis B Virus Replication Andrew V. Stachulski, Chandrakala Pidathala, Eleanor C. Row et al. · Journal of Medicinal Chemistry Open access	9 May 2011	78
26	Nitazoxanide in the treatment of acquired immune deficiency syndrome‐related cryptosporidiosis: results of the United States compassionate use program in 365 patients Jean‐François Rossignol · Alimentary Pharmacology & Therapeutics	16 Aug 2006	78
27	In Vitro Effects of Thiazolides on Giardia lamblia WB Clone C6 Cultured Axenically and in Coculture with Caco2 Cells Joachim Müller, Géraldine Rühle, Norbert Müller et al. · Antimicrobial Agents and Chemotherapy Open access	23 Dec 2005	73
28	The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide Danielle Tilmanis, Carel van Baalen, Ding Yuan Oh et al. · Antiviral Research Open access	3 Oct 2017	65
29	Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide Brent E. Korba, Menashe Elazar, Ping Lui et al. · Antimicrobial Agents and Chemotherapy Open access	18 Aug 2008	63
30	Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication Daria Trabattoni, Federica Gnudi, Salomè V. Ibba et al. · Scientific Reports Open access	2 Jun 2016	59
31	In Vitro Efficacies of Nitazoxanide and Other Thiazolides against Neospora caninum Tachyzoites Reveal Antiparasitic Activity Independent of the Nitro Group Marco Iván Esposito, Rebecca Stettler, Shelley L. Moores et al. · Antimicrobial Agents and Chemotherapy Open access	26 Aug 2005	55
32	Nitazoxanide for the empiric treatment of pediatric infectious diarrhea Jean‐François Rossignol, Nicolás López-Chegne, Luis Martin Julcamoro et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene	Feb 2012	50
33	Thiazolides as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus Replication Andrew V. Stachulski, Chandrakala Pidathala, Eleanor C. Row et al. · Journal of Medicinal Chemistry	7 Nov 2011	47
34	A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 Jean‐François Rossignol, Matthew C. Bardin, Jessica Fulgencio et al. · EClinicalMedicine Open access	28 Feb 2022	46
35	Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides Emmet B. Keeffe, Jean‐François Rossignol · World Journal of Gastroenterology Open access	2009	46
36	Thiazolides: a new class of antiviral drugs Jean‐François Rossignol · Expert Opinion on Drug Metabolism & Toxicology	15 May 2009	45
37	A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B Jean‐François Rossignol, Christian Bréchot · Hepatology Communications Open access	29 Mar 2019	42
38	Treatment of Chronic Hepatitis C Using a 4-week Lead-in With Nitazoxanide Before Peginterferon Plus Nitazoxanide Jean‐François Rossignol, Asem Ahmed Elfert, Emmet B. Keeffe · Journal of Clinical Gastroenterology	26 Mar 2010	40
39	Meeting the Challenge of Eliminating Chronic Hepatitis B Infection Peter A. Revill, Capucine Pénicaud, Christian Bréchot et al. · Genes Open access	Apr 2019	33
40	Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma Frida Ek, Kristin Blom, Tove Selvin et al. · Scientific Reports Open access	27 May 2022	32
41	Inhibitory Activities of Epidermal Growth Factor Receptor Tyrosine Kinase-Targeted Dihydroxyisoflavone and Trihydroxydeoxybenzoin Derivatives on Sarcocystis neurona , Neospora caninum , and Cryptosporidium parvum Development Gilles Gargala, Asiya Baishanbo, Loïc Favennec et al. · Antimicrobial Agents and Chemotherapy Open access	26 Oct 2005	32
42	Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence Anna Riccio, Silvia Santopolo, Antonio Rossi et al. · Cellular and Molecular Life Sciences Open access	7 Apr 2022	31
43	Second-Generation Nitazoxanide Derivatives: Thiazolides are Effective Inhibitors of the Influenza a Virus Andrew V. Stachulski, M. Gabriella Santoro, Sara Piacentini et al. · Future Medicinal Chemistry Open access	Apr 2018	29
44	Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs Andrew V. Stachulski, Karl A. D. Swift, Mark Cooper et al. · European Journal of Medicinal Chemistry Open access	29 Sep 2016	26
45	Syntheses and Antibacterial Activities of Tizoxanide, an N-(Nitrothiazolyl)salicylamide, and its O-Aryl Glucuronide Jean‐François Rossignol, Andrew V. Stachulski · Journal of Chemical Research Synopses	1999	25
46	Short Communication: Nitazoxanide Inhibits HIV Viral Replication in Monocyte-Derived Macrophages Bethsebah Gekonge, Matthew C. Bardin, Luis J. Montaner · AIDS Research and Human Retroviruses Open access	10 Oct 2014	25
47	Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy Edin Jessica Mifsud, Danielle Tilmanis, Ding Yuan Oh et al. · Antiviral Research	20 Feb 2020	23
48	68 RANDOMIZED CONTROLLED TRIAL OF NITAZOXANIDE-PEGINTERFERON-RIBAVIRIN, NITAZOXANIDE-PEGINTERFERON AND PEGINTERFERON-RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 Jean‐François Rossignol, Asem Ahmed Elfert, Y. El-Gohary et al. · Journal of Hepatology	2008	22
49	1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV Mark Sulkowski, Marc Bourlière, J.‐P. Bronowicki et al. · Journal of Hepatology	Apr 2010	22
50	Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir Danielle Tilmanis, Paulina Koszalka, Ian Barr et al. · Antiviral Research	13 Jun 2020	19

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.